Literature DB >> 26699176

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.

Gabriela M Baerlocher, Bart Burington, David S Snyder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26699176     DOI： 10.1056/NEJMc1512663

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.

Authors:  Jamile M Shammo; Brady L Stein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations.

Authors:  Samah Alimam; Donal P McLornan; Jie Jiang; Deepti Radia; Ghulam J Mufti; Claire N Harrison
Journal:  Haematologica       Date:  2017-11-30       Impact factor: 9.941

Review 3.  Novel Therapies for Myelofibrosis.

Authors:  Kristen Pettit; Olatoyosi Odenike
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 4.  Implications of telomeres and telomerase in endometrial pathology.

Authors:  D K Hapangama; A Kamal; G Saretzki
Journal:  Hum Reprod Update       Date:  2017-03-01       Impact factor: 15.610

5.  RNAi modulation of placental sFLT1 for the treatment of preeclampsia.

Authors:  Anton A Turanov; Agnes Lo; Matthew R Hassler; Angela Makris; Ami Ashar-Patel; Julia F Alterman; Andrew H Coles; Reka A Haraszti; Loic Roux; Bruno M D C Godinho; Dimas Echeverria; Suzanne Pears; Jim Iliopoulos; Renuka Shanmugalingam; Robert Ogle; Zsuzsanna K Zsengeller; Annemarie Hennessy; S Ananth Karumanchi; Melissa J Moore; Anastasia Khvorova
Journal:  Nat Biotechnol       Date:  2018-11-19       Impact factor: 54.908

Review 6.  Telomerase reverse transcriptase promoter mutations in thyroid carcinomas: implications in precision oncology-a narrative review.

Authors:  Xiaotian Yuan; Tiantian Liu; Dawei Xu
Journal:  Ann Transl Med       Date:  2020-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.